CN117412972A - 共济失调毛细血管扩张突变(atm)激酶的选择性调节剂和其用途 - Google Patents

共济失调毛细血管扩张突变(atm)激酶的选择性调节剂和其用途 Download PDF

Info

Publication number
CN117412972A
CN117412972A CN202280035588.7A CN202280035588A CN117412972A CN 117412972 A CN117412972 A CN 117412972A CN 202280035588 A CN202280035588 A CN 202280035588A CN 117412972 A CN117412972 A CN 117412972A
Authority
CN
China
Prior art keywords
methyl
imidazo
pyridin
ethoxy
cinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280035588.7A
Other languages
English (en)
Chinese (zh)
Inventor
周鼎
程子强
王铮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Zanrong Medical Technology Co ltd
Original Assignee
Suzhou Zanrong Medical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Zanrong Medical Technology Co ltd filed Critical Suzhou Zanrong Medical Technology Co ltd
Publication of CN117412972A publication Critical patent/CN117412972A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
CN202280035588.7A 2021-03-17 2022-03-15 共济失调毛细血管扩张突变(atm)激酶的选择性调节剂和其用途 Pending CN117412972A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/081254 2021-03-17
PCT/CN2021/081254 WO2022193166A1 (en) 2021-03-17 2021-03-17 Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
PCT/CN2022/080905 WO2022194138A1 (en) 2021-03-17 2022-03-15 Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof

Publications (1)

Publication Number Publication Date
CN117412972A true CN117412972A (zh) 2024-01-16

Family

ID=83321678

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280035588.7A Pending CN117412972A (zh) 2021-03-17 2022-03-15 共济失调毛细血管扩张突变(atm)激酶的选择性调节剂和其用途

Country Status (8)

Country Link
US (1) US20240207263A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308569A4 (cg-RX-API-DMAC7.html)
JP (1) JP7833477B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230157467A (cg-RX-API-DMAC7.html)
CN (1) CN117412972A (cg-RX-API-DMAC7.html)
AU (1) AU2021433713A1 (cg-RX-API-DMAC7.html)
CA (1) CA3213823A1 (cg-RX-API-DMAC7.html)
WO (2) WO2022193166A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021433713A1 (en) * 2021-03-17 2023-09-28 Suzhou Zanrong Pharma Limited Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
JP5542832B2 (ja) 2008-10-24 2014-07-09 アイアールエム・リミテッド・ライアビリティ・カンパニー 生合成的に製造したピロリン−カルボキシ−リシンならびにピロリン−カルボキシ−リシンおよびピロリシン基の化学誘導体化を介する部位特異的タンパク質修飾
NO2714752T3 (cg-RX-API-DMAC7.html) 2014-05-08 2018-04-21
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519406D0 (en) 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN111344293A (zh) * 2017-09-20 2020-06-26 阿斯利康(瑞典)有限公司 1,3-二氢咪唑并[4,5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
WO2020052688A1 (en) * 2018-09-14 2020-03-19 Suzhou Zanrong Pharma Limited 1-ISOPROPYL-3-METHYL-8- (PYRIDIN-3-YL) -1, 3-DIHYDRO-2H-IMIDAZO [4, 5-c] CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF
AU2021433713A1 (en) * 2021-03-17 2023-09-28 Suzhou Zanrong Pharma Limited Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof

Also Published As

Publication number Publication date
EP4308569A1 (en) 2024-01-24
JP2024510762A (ja) 2024-03-11
JP7833477B2 (ja) 2026-03-19
WO2022193166A1 (en) 2022-09-22
US20240207263A1 (en) 2024-06-27
EP4308569A4 (en) 2025-03-05
WO2022194138A1 (en) 2022-09-22
KR20230157467A (ko) 2023-11-16
CA3213823A1 (en) 2022-09-22
AU2021433713A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
US20250092039A1 (en) Glutarimide-containing pan-kras-mutant degrader compounds and uses thereof
ES2670416T3 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento de cáncer
CN114394966B (zh) 吡啶并嘧啶酮cdk2/4/6抑制剂
BR112020010322A2 (pt) composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer
CN115636833B (zh) 作为ATM激酶选择性调节剂的取代的咪唑并[4,5-c]噌啉-2-酮化合物及其用途
ES2686747T3 (es) Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirimidina y derivados de 2,3-dihidro-1H-imidazo[1,2-b]pirazol sustituidos como inhibidores de ROS1
CN114340634A (zh) 作为激酶抑制剂的杂环化合物
EP2571884A2 (en) Mtor selective kinase inhibitors
CN117940437A (zh) Dna-pk选择性抑制剂及其制备方法和用途
WO2023059583A1 (en) Heterobifunctional compounds and their use in treating disease
US20240092761A1 (en) Quinazoline compounds and methods of use
US20240034731A1 (en) Aza-quinazoline compounds and methods of use
TW202417458A (zh) 調節her2的化合物及方法
JPWO2019189555A1 (ja) 複素環化合物
IL319211A (en) Triazine compounds and their uses
JP7833477B2 (ja) 血管拡張性失調症変異(atm)キナーゼの選択的モジュレーターおよびその使用
TW202545531A (zh) 氮—喹唑啉化合物之使用方法
TW202547467A (zh) 雜芳基衍生化合物及其用途
WO2025155742A1 (en) Methods of use for quinazoline compounds
HK40065050A (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
HK40036499A (en) Heterocyclic compounds as prmt5 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination